PharmaEssentia Corporation (6446.TW) Stock Price

6446.TWTAIWAN

PharmaEssentia Corporation is a Taiwanese biopharmaceutical company whose registered address is in Nangang District, Taipei.

NT$1,280.00−6.57%Nov 10 close

Last price · Nov 10, 2026, 05:30 (UTC)

1Y change

+186.84%

Since the Nov 11, 2025 close

6446.TW · 1Y · TWD · 242 observations (daily)

Nov 11, 2025 — Nov 10, 2026. First close: NT$446.24. Latest price: NT$1,280.00.

Show last 20 observations in a table

6446.TW 1Y TWD
Date	Price (TWD)
Oct 13, 2026	NT$1,165.00
Oct 14, 2026	NT$1,190.00
Oct 15, 2026	NT$1,205.00
Oct 16, 2026	NT$1,245.00
Oct 19, 2026	NT$1,175.00
Oct 20, 2026	NT$1,155.00
Oct 21, 2026	NT$1,175.00
Oct 22, 2026	NT$1,160.00
Oct 23, 2026	NT$1,160.00
Oct 27, 2026	NT$1,190.00
Oct 28, 2026	NT$1,200.00
Oct 29, 2026	NT$1,240.00
Oct 30, 2026	NT$1,190.00
Nov 2, 2026	NT$1,190.00
Nov 3, 2026	NT$1,225.00
Nov 4, 2026	NT$1,250.00
Nov 5, 2026	NT$1,185.00
Nov 6, 2026	NT$1,270.00
Nov 9, 2026	NT$1,370.00
Nov 10, 2026	NT$1,280.00

Key statistics

From observed daily candles · based on settled daily closes

52-week range: NT$407.92 – NT$1,645.00
Low Nov 19, 2025 · High Aug 31, 2026
1Y change: +186.84%
Since the Nov 11, 2025 close
Last close: NT$1,280.00
Nov 10, 2026 · −6.57%
Previous close: NT$1,370.00
Nov 9, 2026
Day range: NT$1,275.00 – NT$1,385.00
Nov 10, 2026

Product information

What is PharmaEssentia Corporation (6446.TW)?

PharmaEssentia Corporation is a Taiwanese biopharmaceutical company whose registered address is in Nangang District, Taipei. According to its site, it was founded in 2003 by a group of Taiwanese-American executives and scientists, and it describes itself as a fully integrated global biopharmaceutical company delivering products for the treatment of human diseases. Its shares have traded on the Taiwan Stock Exchange since January 2024 under the code 6446.

The history page records that its ropeginterferon medicine was licensed to AOP Orphan Pharmaceutical in Austria and was developed for conditions such as polycythemia vera, essential thrombocythemia, myelofibrosis and chronic myeloid leukemia. The company page says the firm began from the question of how to unleash the full potential of interferon.

Those following PharmaEssentia usually watch clinical trial stages, licensing and distribution agreements, regulatory approval news and the Taiwan dollar exchange rate. On the Lzzo.com PharmaEssentia page, the price of the shares in Taiwan appears with its observation time, together with a price history chart and technical indicators.

Sources: pharmaessentia.com, openapi.twse.com.tw

Author: Lzzo Editor · Prepared with AI assistance and reviewed by the Lzzo.com editorial team · Editorial policy